Karyopharm Therapeutics
KPTI
#9262
Rank
โ‚น9.02 B
Marketcap
โ‚น529.07
Share price
2.43%
Change (1 day)
-46.04%
Change (1 year)

Revenue for Karyopharm Therapeutics (KPTI)

Revenue in 2025 (TTM): โ‚น12.34 Billion

According to Karyopharm Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚น12.80 Billion. In 2024 the company made a revenue of โ‚น12.45 Billion an increase over the revenue in the year 2023 that were of โ‚น12.15 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Karyopharm Therapeutics from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น12.34 B-0.88%
2024 โ‚น12.45 B2.49%
2023 โ‚น12.15 B-6.47%
2022 โ‚น12.99 B-16.77%
2021 โ‚น15.61 B97.57%
2020 โ‚น7.90 B171.07%
2019 โ‚น2.91 B37.48%
2018 โ‚น2.12 B1969.83%
2017 โ‚น0.10 B879.27%
2016 โ‚น10.46 M-37.01%
2015 โ‚น16.61 M14.97%
2014 โ‚น14.45 M-39.56%
2013 โ‚น23.9 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Merck
MRK
โ‚น5.769 T 44,967.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น4.314 T 33,600.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
โ‚น3.938 T 30,660.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Exelixis
EXEL
โ‚น205.53 B 1,505.43%๐Ÿ‡บ๐Ÿ‡ธ USA